贝伐单抗联合伊立替康治疗转移性结直肠癌的近期疗效观察

目的 探讨贝伐单抗联合伊立替康治疗转移性结直肠癌的疗效。方法 90例患者随机分为3组，30例给予贝伐单抗联合伊立替康治疗（A组），30例使用FOLFIRI方案治疗（B组），30例使用FOLFOX7方案治疗（C组），均给予6个周期治疗。观察患者治疗前后血清肿瘤标志物的动态变化和近期疗效。结果 A组有效率为43-3％，疾病控制率80％：B组有效率为27．7％，疾病控制率53.3％；C组有效率为30．0％，疾病控制率50．0％。3组肿瘤标志物的浓度治疗前后均有明显变化，以A组最为显著（P〈0．05）。结论 贝伐联合伊立替康治疗转移性结直肠癌具有更高的疾病控制率。

Efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer

Objective To evaluate the efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer.Methods Ninety patients were randomly divided into 3 equal groups to receive Avastin plus irinotecan(group A),FOLFIRI(group B)and FOLFOX7(group C)for two cycles,respectively.The response rate and changes in tumor maker levels were observed.Results The tumor response rate was 43.3% in group A,27.7% in group B and 30.0% in group C.The disease control rate(complete response partial response stable disease)was 80% in group A,53.3% in group B and 50.0% in group C.Obvious changes in tumor marker levels were observed in the 3 groups after treatment,which were most conspicuous in group A(P<0.05).Conclusion The addition of Avastin to irinotecan chemotherapy results in significant improvement of clinical efficacy in patients with metastatic colorectal cancer.